2025
A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.
Sadeghi S, Callis S, Lara P, Berg S, Brown J, Bangs R, Nakagawa D, Daneshmand S, Ian Murchie Jr., Flaig T, Petrylak D, Lerner S. A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design. Journal Of Clinical Oncology 2025, 43: tps887-tps887. DOI: 10.1200/jco.2025.43.5_suppl.tps887.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaProgression-free survivalStandard of careEnfortumab vedotinOverall survivalCisplatin-ineligible metastatic urothelial carcinomaMedian progression-free survivalPhase III randomized trialStudies of eribulinMedian overall survivalPlatinum-based chemotherapyLines of therapyEndpoint of OSOne-sided alphaFGFR3 alterationsLiver metastasesSystemic therapyEligible ptsUrothelial carcinomaPrimary endpointSecondary endpointsGenitourinary cancersEribulinTreatment changesGemcitabine
2012
1666 SWOG S0353 PHASE II TRIAL OF INTRAVESICAL GEMCITABINE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER WHO RECURRED FOLLOWING AT LEAST TWO PRIOR COURSES OF BCG
Skinner E, Goldman B, Sakr W, Petrylak D, Lenz H, Lee C, Wilson S, Lerner S, Tangen C, Thompson I. 1666 SWOG S0353 PHASE II TRIAL OF INTRAVESICAL GEMCITABINE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER WHO RECURRED FOLLOWING AT LEAST TWO PRIOR COURSES OF BCG. Journal Of Urology 2012, 187: e673. DOI: 10.1016/j.juro.2012.02.1524.Peer-Reviewed Original Research
2005
Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial
Hussain M, Petrylak D, Dunn R, Vaishampayan U, Lara P, Chatta G, Nanus D, Glode L, Trump D, Chen H, Smith D. Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial. Journal Of Clinical Oncology 2005, 23: 4507-4507. DOI: 10.1200/jco.2005.23.16_suppl.4507.Peer-Reviewed Original Research
2004
Paclitaxel, carboplatin and gemcitabine (PCG) as neoadjuvant therapy in patients with locally advanced transitional cell carcinoma (TCC) of the bladder
Smith D, Bhandari M, Hussain M, Montie J, Wood D, Lee C, Petrylak D, Vaishampayan U. Paclitaxel, carboplatin and gemcitabine (PCG) as neoadjuvant therapy in patients with locally advanced transitional cell carcinoma (TCC) of the bladder. Journal Of Clinical Oncology 2004, 22: 4541-4541. DOI: 10.1200/jco.2004.22.14_suppl.4541.Peer-Reviewed Original ResearchPhase I/II study of docetaxel (D), gemcitabine (G), Carboplatin (C) in poor prognosis and previously treated patients (pts) with urothelial carcinoma (UTC)
Chen A, Hovey E, Shelton G, Fitzsimmons J, Randall A, Taub R, Petrylak D. Phase I/II study of docetaxel (D), gemcitabine (G), Carboplatin (C) in poor prognosis and previously treated patients (pts) with urothelial carcinoma (UTC). Journal Of Clinical Oncology 2004, 22: 4580-4580. DOI: 10.1200/jco.2004.22.14_suppl.4580.Peer-Reviewed Original ResearchPaclitaxel, carboplatin and gemcitabine (PCG) as neoadjuvant therapy in patients with locally advanced transitional cell carcinoma (TCC) of the bladder
Smith D, Bhandari M, Hussain M, Montie J, Wood D, Lee C, Petrylak D, Vaishampayan U. Paclitaxel, carboplatin and gemcitabine (PCG) as neoadjuvant therapy in patients with locally advanced transitional cell carcinoma (TCC) of the bladder. Journal Of Clinical Oncology 2004, 22: 4541-4541. DOI: 10.1200/jco.2004.22.90140.4541.Peer-Reviewed Original ResearchPhase I/II study of docetaxel (D), gemcitabine (G), Carboplatin (C) in poor prognosis and previously treated patients (pts) with urothelial carcinoma (UTC)
Chen A, Hovey E, Shelton G, Fitzsimmons J, Randall A, Taub R, Petrylak D. Phase I/II study of docetaxel (D), gemcitabine (G), Carboplatin (C) in poor prognosis and previously treated patients (pts) with urothelial carcinoma (UTC). Journal Of Clinical Oncology 2004, 22: 4580-4580. DOI: 10.1200/jco.2004.22.90140.4580.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply